Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026)

Sarepta Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 95.23% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $60.4 million (down 59.23% YoY), while the FY2025 annual figure was $102.0 million, down 25.54% from the prior year.
• Capital Expenditures was $2.1 million for Q1 2026 at Sarepta Therapeutics, down from $3.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $43.7 million in Q1 2025 to a low of $2.1 million in Q1 2026.
• Historically, Capital Expenditures has averaged $20.5 million across 5 years, with a median of $19.0 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Capital Expenditures soared 261.02% in 2022, then tumbled 95.23% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $8.0 million in 2022, then jumped by 139.06% to $19.0 million in 2023, then jumped by 100.02% to $38.1 million in 2024, then plunged by 90.57% to $3.6 million in 2025, then tumbled by 42.05% to $2.1 million in 2026.
• The last three Capital Expenditures figures came in at $2.1 million (Q1 2026), $3.6 million (Q4 2025), and $22.9 million (Q3 2025), per Business Quant data.